公开(公告)号：US20200085904A1

公开(公告)日：2020-03-19

申请号：US16494609

申请日：2018-03-18

申请人： KERALA AYURVEDA LIMITED (INDIA) ,  KATRA PHYTOCHEM (INDIA) PRIVATE LIMITED

发明人： Patanjali SUBRAMONI ,  Sundaram CHANDRASEKHARAN ,  Jayashree MADHAVAN ,  Anilkumar K ,  Sarala SAMUEL ,  Bishwajit NAG ,  Ramesh VANGAL ,  Nitish NAG ,  Jayarajan KODIKANNATH

IPC分类号： A61K36/9066 ,  A61K36/185 ,  A61K36/28 ,  A61K36/59 ,  A61K36/48 ,  A61K36/74 ,  A61K36/61 ,  A61K9/00

摘要： The present invention generally relates to an herbal composition effective in management of disorders related to metabolic syndrome. More particularly, the invention relates to an herbal composition effective in the management of disorders related to metabolic syndrome such as Type 2 diabetes mellitus, obesity and lipid profile management and a process for the preparation of such an herbal composition. The invention further relates to the use of the herbal composition in preparation of food supplements, pharmaceuticals and nutraceuticals for the management of disorders related to metabolic syndrome. The herbal composition effective in management of metabolic syndrome related disorders comprises of herbs selected from Curcuma longa, Emblica officinalis, Vernonia anthelmintica, Tinospora cordifolia, Trigonella foenum-graecum, Ixora coccinea and Syzygium cumini. Also provided is the use of herbal composition for the treatment of disorders related to metabolic syndrome. Also provided is a method of treating disorders related to metabolic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of the herbal composition of the present invention.

公开(公告)号：US10576117B2

公开(公告)日：2020-03-03

申请号：US16232573

申请日：2018-12-26

申请人： Muniyal Ayurvedic Research Centre

发明人： M Vijayabhanu Shetty

IPC分类号： A61K36/00 ,  A61K36/25 ,  A61K36/185 ,  A61K36/9066 ,  A61K36/37 ,  A61K36/24 ,  A61K36/61 ,  A61K36/59 ,  A61K45/06 ,  A61P3/10 ,  A61K36/328 ,  A61K36/9068 ,  A61K36/67 ,  A61K33/30 ,  A61K35/614

摘要： Herbo-mineral formulation for prevention, treatment and management of Diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating Diabetes and Diabetes associated complications. Further the disclosed formulation has been observed to exhibit hypoglycemic, hypolipidemic, and pancreatic cell regenerative properties.

公开(公告)号：US10568925B2

公开(公告)日：2020-02-25

申请号：US15011628

申请日：2016-01-31

申请人： DHARMA BIOMEDICAL, LLC ,  FLAVEX NATUREXTRAKTE GMBH

发明人： Steven J. Melnick ,  Karl-Werner Quirin ,  Cheppail Ramachandran ,  Melvin Rothberg

IPC分类号： A61K36/9066 ,  A61K31/11 ,  A61K31/015 ,  A61K31/01 ,  A61K45/06

摘要： The invention concerns carbon dioxide extracts of Curcuma amada (mango ginger), including supercritical carbon dioxide extracts of C. amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of Bcl-2, Bak, and p53 genes; inhibiting expression of the COX-2 and NF-kB genes, inhibiting production of phosphorylated target of rapamycin (TOR), modulating AMP-activated protein kinase (AMPK), inhibiting protein kinase B (AKT) signaling, modulating the Ras/Raf/MEK/ERK signaling pathway, and modulating the Ras/PI3K/PTEN/Akt/mTOR signaling pathway. Another aspect of the invention concerns a method for inhibiting contamination, comprising applying the extract or composition of the invention to a surface. Another aspect of the invention concerns a method for promoting longevity of a cell in vitro or in vivo, comprising contacting a target cell in vitro or in vivo with an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a method for promoting longevity of a subject, comprising administering an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a method for inhibiting the metabolism of a cancer cell, comprising contacting the target cancer cell in vitro or in vivo with an effective amount of the extract or composition of the invention. Another aspect of the invention concerns a kit including the extract or composition; a container containing the extract or composition; and packaging material.

公开(公告)号：US10561701B2

公开(公告)日：2020-02-18

申请号：US16115695

申请日：2018-08-29

申请人： DATT MEDIPRODUCTS LIMITED ,  DATT LIFE SCIENCE PVT. LTD.

发明人： Rajan Datt ,  Siddharth Pandey ,  Pallavi Shrivastava ,  Ramadhar Kumar

IPC分类号： A61K36/9066 ,  A61K36/886 ,  A61K36/47 ,  A61K33/38 ,  A61K36/82 ,  A61F13/00 ,  A61K9/70 ,  A61K31/765 ,  A61K36/185 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61L15/18 ,  A61L15/20 ,  A61L15/22 ,  A61L15/40 ,  A61L15/42 ,  A61L15/44 ,  A61L15/58 ,  A61L15/32

摘要： This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phyto-pharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.

公开(公告)号：US20200038468A1

公开(公告)日：2020-02-06

申请号：US16499666

申请日：2018-04-03

申请人： TCI CO., LTD.

发明人： Yung-Hsiang LIN ,  I-Hui CHEN ,  Kai-Wen KAN ,  Fu Chen LIU ,  Ciao-Ting CHEN

IPC分类号： A61K36/82 ,  A61K36/45 ,  A61K36/87 ,  A61K36/752 ,  A61K36/67 ,  A61K36/31 ,  A61K36/886 ,  A61K36/8962 ,  A61K36/21 ,  A61K36/53 ,  A61K36/9066 ,  A61K36/258 ,  A61K36/48 ,  A61K31/01 ,  A61K36/74 ,  A61K36/73 ,  A61K31/015 ,  A61K36/815 ,  A61P3/04

摘要： Provided is a composition for reducing the fat content of fat-producing cells and applications thereof. The composition includes plant extracts such as a blueberry extract and a black tea extract.

公开(公告)号：US20200038319A1

公开(公告)日：2020-02-06

申请号：US16527908

申请日：2019-07-31

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA

发明人： Kristi Crowe-White

IPC分类号： A61K9/68 ,  A61K36/537 ,  A61K36/54 ,  A61K36/534 ,  A61K36/82 ,  A61K36/8962 ,  A61K36/9068 ,  A61K36/66 ,  A61K36/752 ,  A61K36/9066 ,  A61Q11/00 ,  A23L27/10 ,  A23L33/135 ,  A61K8/67

摘要： Disclosed herein are compositions and methods for treating, reducing or preventing oxidative stress in a subject. The compositions can be chewable confectionaries comprising a chewable base, one or more unprocessed phytochemical ingredients, and a sweetener comprising allulose. The unprocessed phytochemical ingredients can include ground plant materials selected from cinnamon, nutmeg, allspice, or combinations thereof. The chewable confectionary can exhibit a polyphenolic content of at least 100 μg gallic acid equivalents (GAE) or greater, per gram of the chewable confectionary and an antioxidant capacity of at least 3,200 μM Trolox equivalents per gram of the chewable confectionary, as determined by the oxygen radical absorbance (ORAC) assay. Kits, methods of making and using the chewable confectionary are also disclosed.

公开(公告)号：US10542989B2

公开(公告)日：2020-01-28

申请号：US15897886

申请日：2018-02-15

申请人： LAILA NUTRACEUTICALS

发明人： Ganga Raju Gokaraju ,  Rama Raju Gokaraju ,  Venketa Kanaka Ranga Raju Gokaraju ,  Kiran Bhupathiraju ,  Trimurtulu Golakati ,  Krishanu Sengupta ,  Venkata Krishna Raju Alluri

IPC分类号： A61K36/00 ,  A61B17/11 ,  A61F2/06 ,  A61K36/28 ,  A61K36/9066 ,  A61K36/38 ,  A61K36/53 ,  A61K36/54 ,  A23L33/105

摘要： The present invention discloses novel synergistic dietary supplement compositions comprising at least two ingredients selected from the extracts and fractions derived from Sphaeranthus indicus, Coleus aromaticus, Cissus quadrangularis, Curcuma longa, Garcinia mangostana, Citrullus lanatus, Ocimum sanctum, Trachyspermum ammi and Cinnamomum tamala as natural energy enhancer for enhancing physical performance, muscle strength, muscle mass, mental alertness and energy levels in a mammal.

公开(公告)号：US10537548B2

公开(公告)日：2020-01-21

申请号：US15936695

申请日：2018-03-27

申请人： Caliway Biopharmaceuticals Co., Ltd.

发明人： Yu-Fang Ling

IPC分类号： A61K8/06 ,  A61K31/353 ,  A23F3/16 ,  A61K45/06 ,  A61K36/82 ,  A61K31/12 ,  A61K31/4184 ,  A61K36/9066 ,  A23L33/105

摘要： The present invention discloses a composition and its pharmaceutical composition for reducing body weight and body fat, and a use of said product The composition comprises epigallocatechin gallate, curcumin, and an excipient, wherein the excipient comprises at least one of glyceryl dibehenate, polyoxyethylene stearates, polysorbate 80 mixture, vitamin E polyethylene glycol succinate, glyceryl monostearate, and oleoyl polyoxyl-6 glycerides, or a combination thereof; the polysorbate 80 mixture comprises polysorbate 80 and magnesium aluminometasilicate. In animal testing where obesity is induced either prior to or during testing, use of the composition of the present invention leads to a significant reduction of body weight and body fat.

公开(公告)号：US10512616B2

公开(公告)日：2019-12-24

申请号：US15844459

申请日：2017-12-15

申请人： Arjuna Natural Private Limited

发明人： Benny Antony

IPC分类号： A61K36/00 ,  A61K31/12 ,  A61K36/9066 ,  A61K47/08

摘要： A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric.

公开(公告)号：US10478418B2

公开(公告)日：2019-11-19

申请号：US16128786

申请日：2018-09-12

申请人： IN Ingredients, Inc.

发明人： Augustin T. Romero ,  Bolin Qin

IPC分类号： A61K36/00 ,  A61K31/357 ,  A61K36/53 ,  A61K36/9066 ,  A61K36/63 ,  A61K36/73 ,  A61K31/353 ,  A61K31/7048 ,  A61K36/49 ,  A61K9/00

摘要： Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.